Browse CLDN18

Summary
SymbolCLDN18
Nameclaudin 18
Aliases SFTPJ; surfactant associated protein J; SFTA5; surfactant associated 5; surfactant, pulmonary associated pro ......
Chromosomal Location3q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell junction, tight junction. Cell membrane; Multi-pass membrane protein.
Domain PF00822 PMP-22/EMP/MP20/Claudin family
Function

Plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity.

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0001894 tissue homeostasis
GO:0002521 leukocyte differentiation
GO:0002573 myeloid leukocyte differentiation
GO:0002683 negative regulation of immune system process
GO:0002761 regulation of myeloid leukocyte differentiation
GO:0002762 negative regulation of myeloid leukocyte differentiation
GO:0010721 negative regulation of cell development
GO:0016338 calcium-independent cell-cell adhesion via plasma membrane cell-adhesion molecules
GO:0030099 myeloid cell differentiation
GO:0030316 osteoclast differentiation
GO:0032844 regulation of homeostatic process
GO:0032845 negative regulation of homeostatic process
GO:0033209 tumor necrosis factor-mediated signaling pathway
GO:0034103 regulation of tissue remodeling
GO:0034104 negative regulation of tissue remodeling
GO:0034504 protein localization to nucleus
GO:0034612 response to tumor necrosis factor
GO:0036035 osteoclast development
GO:0045124 regulation of bone resorption
GO:0045453 bone resorption
GO:0045637 regulation of myeloid cell differentiation
GO:0045638 negative regulation of myeloid cell differentiation
GO:0045670 regulation of osteoclast differentiation
GO:0045671 negative regulation of osteoclast differentiation
GO:0045779 negative regulation of bone resorption
GO:0046849 bone remodeling
GO:0046850 regulation of bone remodeling
GO:0046851 negative regulation of bone remodeling
GO:0048565 digestive tract development
GO:0048771 tissue remodeling
GO:0048871 multicellular organismal homeostasis
GO:0055123 digestive system development
GO:0060249 anatomical structure homeostasis
GO:0060348 bone development
GO:0061515 myeloid cell development
GO:0071356 cellular response to tumor necrosis factor
GO:0071847 TNFSF11-mediated signaling pathway
GO:0098742 cell-cell adhesion via plasma-membrane adhesion molecules
GO:0098751 bone cell development
GO:1900180 regulation of protein localization to nucleus
GO:1900181 negative regulation of protein localization to nucleus
GO:1902105 regulation of leukocyte differentiation
GO:1902106 negative regulation of leukocyte differentiation
GO:1903010 regulation of bone development
GO:1903011 negative regulation of bone development
GO:1903706 regulation of hemopoiesis
GO:1903707 negative regulation of hemopoiesis
GO:1903828 negative regulation of cellular protein localization
GO:2001204 regulation of osteoclast development
GO:2001205 negative regulation of osteoclast development
Molecular Function -
Cellular Component GO:0005923 bicellular tight junction
GO:0043296 apical junction complex
GO:0070160 occluding junction
> KEGG and Reactome Pathway
 
KEGG hsa04514 Cell adhesion molecules (CAMs)
hsa04530 Tight junction
hsa04670 Leukocyte transendothelial migration
Reactome R-HSA-446728: Cell junction organization
R-HSA-1500931: Cell-Cell communication
R-HSA-421270: Cell-cell junction organization
R-HSA-420029: Tight junction interactions
Summary
SymbolCLDN18
Nameclaudin 18
Aliases SFTPJ; surfactant associated protein J; SFTA5; surfactant associated 5; surfactant, pulmonary associated pro ......
Chromosomal Location3q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CLDN18 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolCLDN18
Nameclaudin 18
Aliases SFTPJ; surfactant associated protein J; SFTA5; surfactant associated 5; surfactant, pulmonary associated pro ......
Chromosomal Location3q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CLDN18 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCLDN18
Nameclaudin 18
Aliases SFTPJ; surfactant associated protein J; SFTA5; surfactant associated 5; surfactant, pulmonary associated pro ......
Chromosomal Location3q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CLDN18 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.9660.125
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.80.581
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.1780.519
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2170.776
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.160.886
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.4120.74
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0110.979
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.1520.811
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.7130.0339
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CLDN18 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCLDN18
Nameclaudin 18
Aliases SFTPJ; surfactant associated protein J; SFTA5; surfactant associated 5; surfactant, pulmonary associated pro ......
Chromosomal Location3q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CLDN18. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCLDN18
Nameclaudin 18
Aliases SFTPJ; surfactant associated protein J; SFTA5; surfactant associated 5; surfactant, pulmonary associated pro ......
Chromosomal Location3q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CLDN18. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CLDN18.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCLDN18
Nameclaudin 18
Aliases SFTPJ; surfactant associated protein J; SFTA5; surfactant associated 5; surfactant, pulmonary associated pro ......
Chromosomal Location3q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CLDN18. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCLDN18
Nameclaudin 18
Aliases SFTPJ; surfactant associated protein J; SFTA5; surfactant associated 5; surfactant, pulmonary associated pro ......
Chromosomal Location3q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CLDN18 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCLDN18
Nameclaudin 18
Aliases SFTPJ; surfactant associated protein J; SFTA5; surfactant associated 5; surfactant, pulmonary associated pro ......
Chromosomal Location3q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CLDN18 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCLDN18
Nameclaudin 18
Aliases SFTPJ; surfactant associated protein J; SFTA5; surfactant associated 5; surfactant, pulmonary associated pro ......
Chromosomal Location3q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CLDN18 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.